Please sign in to follow a disease.
New study monitors RSV vaccine safety in seniors
NCT ID NCT06546800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking the safety of the Abrysvo RSV vaccine in adults aged 60 and older in everyday medical practice in Japan. About 1100 people who get the vaccine will be watched for side effects for 28 days. The goal is to confirm the vaccine is safe for older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals aged 60 years or older who have been vaccinated with Abrysvo for the first time.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Individuals aged 60 years or older who have been vaccinated with Abrysvo for the first time after Abrysvo is launched. Those who have previously participated in the clinical trials of this product will be excluded. 2. Vaccinated participants (or his/her legally acceptable representative) who understand the information on this study and have provided written consent regarding their participation in the study. Exclusion Criteria: -There are no exclusion criteria for this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test catch flu in High-HIV regions?
- RSV drug trial for kids under 5 halted early – only 4 children enrolled
- Could a shot for moms shield babies from deadly RSV?
- RSV study seeks immune clues in older adults
- New study aims to predict severe bronchiolitis in infants
- New RSV vaccine shows promise for seniors in large trial